Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yessar Hussain

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Clinical Neuromuscular Disease|August 25, 2021
Variable Presentation of Hereditary Transthyretin-Mediated Amyloidosis at a Single CenterYessar Hussain
Neurologic Clinics|July 25, 2020
Other MyopathiesYessar Hussain, Samantha Miller
Annals of Clinical and Translational Neurology|February 8, 2021
Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathiesChiseko Ikenaga, Andrew R Findlay, Namita A Goyal, et al.
Annals of Clinical and Translational Neurology|April 14, 2025
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia GravisAli A Habib, Kristl G Claeys, Vera Bril, et al.
Annals of Medicine|September 20, 2025
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter studyYessar Hussain, Saurabh Malhotra, Brett W Sperry, et al.
The Lancet. Rheumatology|March 16, 2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trialAndrew L Mammen, Anthony A Amato, Mazen M Dimachkie, et al.
Muscle & Nerve|May 21, 2022
Patient preference for virtual versus in-person visits in neuromuscular clinical practiceKomal Hafeez, Hani Kushlaf, Husam Al-Sultani, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Clinical Neuromuscular Disease|August 25, 2021
Variable Presentation of Hereditary Transthyretin-Mediated Amyloidosis at a Single CenterYessar Hussain
Neurologic Clinics|July 25, 2020
Other MyopathiesYessar Hussain, Samantha Miller
Annals of Clinical and Translational Neurology|February 8, 2021
Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathiesChiseko Ikenaga, Andrew R Findlay, Namita A Goyal, et al.
Annals of Clinical and Translational Neurology|April 14, 2025
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia GravisAli A Habib, Kristl G Claeys, Vera Bril, et al.
Annals of Medicine|September 20, 2025
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter studyYessar Hussain, Saurabh Malhotra, Brett W Sperry, et al.
The Lancet. Rheumatology|March 16, 2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trialAndrew L Mammen, Anthony A Amato, Mazen M Dimachkie, et al.
Muscle & Nerve|May 21, 2022
Patient preference for virtual versus in-person visits in neuromuscular clinical practiceKomal Hafeez, Hani Kushlaf, Husam Al-Sultani, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Pageof 2